JP7134168B6 - 新規使用 - Google Patents

新規使用 Download PDF

Info

Publication number
JP7134168B6
JP7134168B6 JP2019513845A JP2019513845A JP7134168B6 JP 7134168 B6 JP7134168 B6 JP 7134168B6 JP 2019513845 A JP2019513845 A JP 2019513845A JP 2019513845 A JP2019513845 A JP 2019513845A JP 7134168 B6 JP7134168 B6 JP 7134168B6
Authority
JP
Japan
Prior art keywords
alkyl
pde1
formula
lps
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019513845A
Other languages
English (en)
Japanese (ja)
Other versions
JP7134168B2 (ja
JP2019531285A5 (https=
JP2019531285A (ja
Inventor
グレッチェン・スナイダー
ローレンス・ピー・ウェノグル
ジェニファー・オブライエン
ジョゼフ・ヘンドリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of JP2019531285A publication Critical patent/JP2019531285A/ja
Publication of JP2019531285A5 publication Critical patent/JP2019531285A5/ja
Priority to JP2022098388A priority Critical patent/JP7506711B2/ja
Application granted granted Critical
Publication of JP7134168B2 publication Critical patent/JP7134168B2/ja
Publication of JP7134168B6 publication Critical patent/JP7134168B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019513845A 2016-09-12 2017-09-12 新規使用 Active JP7134168B6 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022098388A JP7506711B2 (ja) 2016-09-12 2022-06-17 新規使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662393386P 2016-09-12 2016-09-12
US62/393,386 2016-09-12
US201662412739P 2016-10-25 2016-10-25
US62/412,739 2016-10-25
US201762467218P 2017-03-05 2017-03-05
US62/467,218 2017-03-05
PCT/US2017/051220 WO2018049417A1 (en) 2016-09-12 2017-09-12 Novel uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022098388A Division JP7506711B2 (ja) 2016-09-12 2022-06-17 新規使用

Publications (4)

Publication Number Publication Date
JP2019531285A JP2019531285A (ja) 2019-10-31
JP2019531285A5 JP2019531285A5 (https=) 2021-05-06
JP7134168B2 JP7134168B2 (ja) 2022-09-09
JP7134168B6 true JP7134168B6 (ja) 2024-02-02

Family

ID=61562179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019513845A Active JP7134168B6 (ja) 2016-09-12 2017-09-12 新規使用
JP2022098388A Active JP7506711B2 (ja) 2016-09-12 2022-06-17 新規使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022098388A Active JP7506711B2 (ja) 2016-09-12 2022-06-17 新規使用

Country Status (5)

Country Link
US (1) US11291666B2 (https=)
EP (2) EP3509589B1 (https=)
JP (2) JP7134168B6 (https=)
ES (1) ES2906107T3 (https=)
WO (1) WO2018049417A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
US10682354B2 (en) * 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP7134168B6 (ja) * 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
MX2020012628A (es) 2018-05-25 2021-01-29 Intra Cellular Therapies Inc Compuestos organicos.
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
US20210338679A1 (en) * 2018-09-25 2021-11-04 Intra-Cellular Therapies, Inc. Novel uses
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US11628171B2 (en) 2019-03-13 2023-04-18 Children's Medical Center Corporation Method for treating brain or nerve injury
KR20220054853A (ko) 2019-09-03 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 치료 방법
JP2023505054A (ja) * 2019-11-27 2023-02-08 イントラ－セルラー・セラピーズ・インコーポレイテッド 処置方法
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease
MX2024010993A (es) * 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.
CN119486738A (zh) 2022-05-18 2025-02-18 细胞内治疗公司 新方法
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
WO2025255013A1 (en) * 2024-06-03 2025-12-11 Intra-Cellular Therapies, Inc. Organic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512842A (ja) 2013-03-15 2016-05-09 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032638B2 (ja) 1976-09-01 1985-07-29 武田薬品工業株式会社 ３−アミノピラゾロ〔３，４−ｄ〕ピリミジン誘導体
EP0077372A1 (de) 1981-04-22 1983-04-27 Byk Gulden Lomberg Chemische Fabrik GmbH NEUE PYRAZOLO(3,4-d)PYRIMIDINE, VERFAHREN ZU DEREN HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL
US4469868A (en) 1982-05-24 1984-09-04 Warner-Lambert Company Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines
US4690935A (en) 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
KR920004437B1 (ko) 1989-09-12 1992-06-05 삼성전자 주식회사 금전등록기의 거래선 관리방법
NZ238609A (en) 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5939419A (en) 1993-02-26 1999-08-17 Schering-Plough Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5824683A (en) 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6013621A (en) 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
EP1067123B1 (en) 1998-03-31 2011-01-19 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
US6133273A (en) 1998-05-08 2000-10-17 American Home Products Corporation Pyrazolopyrimidine-2,4-dione sulfonamides
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
EP1194152A4 (en) 1999-06-30 2002-11-06 Merck & Co Inc Links to SRC kinase inhibition
WO2001000213A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
DE19931206A1 (de) 1999-07-07 2001-01-11 Stief Christian Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
AU779908B2 (en) 1999-09-10 2005-02-17 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2379585C (en) 1999-09-30 2006-06-20 James W. Darrow Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
HK1049834A1 (zh) 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US20020006926A1 (en) 2000-04-19 2002-01-17 Roylance H. H. Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
WO2002074312A1 (en) 2001-03-16 2002-09-26 Pfizer Limited Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
ATE395349T1 (de) 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
IL160307A0 (en) 2001-08-31 2004-07-25 Univ Rockefeller Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
CA2465893A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
AU2003219770B2 (en) 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
IL163575A0 (en) 2002-02-21 2005-12-18 Univ Rockefeller Compositions and method for regulation of calcium-dependent signalling in brain
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
CA2499170A1 (en) 2002-09-27 2004-04-08 Children's Medical Center Corporation Methods and compositions for treatment of neurological disorder
AU2003276009A1 (en) 2002-10-01 2004-04-23 Bayer Healthcare Ag Regulation of human 3', 5' cyclic nucleotide phosphodiesterase pde1c
US20070155662A1 (en) 2003-03-11 2007-07-05 Stefan Golz Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
EP1613747A1 (en) 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
AR045582A1 (es) 2003-09-05 2005-11-02 Neurogen Corp Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1
US20050287665A1 (en) 2004-06-23 2005-12-29 Henrich Cheng Method for inducing neural differentiation
JP5132310B2 (ja) 2004-09-08 2013-01-30 スパイナル・モデュレーション・インコーポレイテッド 神経刺激の方法及びシステム
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
KR20090042227A (ko) 2006-06-06 2009-04-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US20070286890A1 (en) 2006-06-07 2007-12-13 John Garnett Walt Eyelash applicator and method
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
JP5498392B2 (ja) * 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2240028B1 (en) 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
MA32942B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
KR20110103949A (ko) 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2367431B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Organic compounds
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2011043816A1 (en) 2009-10-08 2011-04-14 Intra-Cellular Therapies, Inc. Phosphodiesterase 1-targeting tracers and methods
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP2014525927A (ja) 2011-08-18 2014-10-02 シャイアー アーゲー 治療法に使用される５−ｈｔ４受容体アゴニスト及びｐｄｅ４阻害剤の組合せ
JP6224597B2 (ja) 2011-09-27 2017-11-01 バイオメッド バレー ディスカバリーズ，インコーポレイティド グリオーマを処置するための組成物及び方法
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
US9801882B2 (en) * 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
EP3157926B1 (en) 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organic compounds
CA2969594A1 (en) * 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Pde2 inhibiting organic compounds
JP2018515474A (ja) 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
TW201920104A (zh) 2017-08-31 2019-06-01 美商馬愈法瑪公司 外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制劑及其用途
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512842A (ja) 2013-03-15 2016-05-09 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Current Opinion in Pharmacology，2007年，7，86-92
Experimental Neurology，2013年，247，80-90
Frontiers in Neuroscience，2011年，5，Article 21
Journal of Medical Chemistry，2016年，59，1149-1164
Progress in Neuro-Psychopharmacology & Biological Psychiatry，2014年，277-286
Psychopharmacology，2016年，233，3113-3124

Also Published As

Publication number Publication date
JP2022137064A (ja) 2022-09-21
JP7506711B2 (ja) 2024-06-26
EP3509589B1 (en) 2021-11-17
WO2018049417A1 (en) 2018-03-15
EP3970719A1 (en) 2022-03-23
ES2906107T3 (es) 2022-04-13
JP7134168B2 (ja) 2022-09-09
US20210213018A1 (en) 2021-07-15
EP3509589A1 (en) 2019-07-17
US11291666B2 (en) 2022-04-05
EP3509589A4 (en) 2020-03-18
JP2019531285A (ja) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7506711B2 (ja) 新規使用
RU2679142C2 (ru) Органические соединения
EP3479825B1 (en) Pde1 inhibitors for use in the treatment and/or prevention of cns or pns diseases or disorders
JP6872541B2 (ja) ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物
JP6696904B2 (ja) 製剤および医薬組成物
KR20090013834A (ko) 피리도[3,2-ｅ]피라진, 포스포디에스테라제 10의 억제제로서 이의 용도, 및 이의 제조 방법
EP2968322B1 (en) Map kinase modulators and uses thereof
EP3725789B1 (en) 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
CN104136428A (zh) 用于抑制bcl2与结合配偶体相互作用的化合物
US11851427B2 (en) Phosphodiesterase inhibitors and uses thereof
EP3091982B1 (en) Organic compounds
US10626113B2 (en) Phosphodiesterase inhibitors and uses thereof
CN103958509B (zh) 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
US11628171B2 (en) Method for treating brain or nerve injury
JP2022545802A (ja) 有機化合物
HK40040400B (en) 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
HK40040400A (en) 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns)
HK40012670B (en) Pyrazine compounds as map kinase modulators and uses thereof
HK40012670A (en) Pyrazine compounds as map kinase modulators and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220617

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220628

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220830

R150 Certificate of patent or registration of utility model

Ref document number: 7134168

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250